Toxicology News and Research RSS Feed - Toxicology News and Research

Toxicology is the study of harmful interactions between chemical, physical, or biological agents and biological systems.
Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. [More]
Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China. [More]

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Wednesday, April 9, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. [More]

Research provides new approach to developing better treatment options for scleroderma

Scleroderma is a rare and often fatal disease, causing the thickening of tissue, that currently lacks a cure and any effective treatments. A group of researchers, including a Michigan State University professor, is looking to change that. [More]

Affygility’s occupational exposure limit monograph is now available for delta-9-tetrahydrocannabinol

Affygility Solutions is pleased to announce that its occupational exposure limit monograph is now available for delta-9-tetrahydrocannabinol, the principal psychoactive ingredient in marijuana. [More]
ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). [More]
BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma. [More]

ATHENA develops surrogate organ system for toxicity testing

Creating surrogate human organs, coupled with insights from highly sensitive mass spectrometry technologies, a new project is on the brink of revolutionizing the way we screen new drugs and toxic agents. [More]

Study: Guinea pigs and mice can be replaced with non-animal skin sensitization method

Guinea pigs and mice can be replaced with a non-animal skin sensitization method that uses a human-derived skin model, according to a study presented today by the PETA International Science Consortium, Ltd., at the Society of Toxicology's annual meeting. [More]
Researchers explore link between diet, metabolic homeostasis and air pollutant exposure

Researchers explore link between diet, metabolic homeostasis and air pollutant exposure

Is air pollution connected with increases in obesity, diabetes, and chronic kidney disease? Researchers are providing insight into that question today at the Society of Toxicology 53rd Annual Meeting and ToxExpo in Phoenix, Ariz. [More]

Toxicologists reveal new methods for estimating infants' exposure to POPs

Toxicologists are revealing new methods and models for estimating infants' exposure to persistent organic pollutants (POPs) today at the Society of Toxicology (SOT) 53rd Annual Meeting and ToxExpo in Phoenix, Ariz. [More]
Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University. [More]

Study: Role of alcohol in U.S. traffic deaths may be underreported on death certificates

It's no secret that drinking and driving can be a deadly mix. But the role of alcohol in U.S. traffic deaths may be substantially underreported on death certificates, according to a study in the March issue of the Journal of Studies on Alcohol and Drugs. [More]

Patients who receive help from poison center have shorter hospital stays and lower medical costs

Patients who received help from a poison center had shorter hospital stays and lower hospital charges among those who are the most expensive to treat, according to a study led by researchers at the University of Illinois at Chicago School of Public Health. [More]

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism. [More]
A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria. [More]

Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock

Alere Inc., a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock. [More]

Exposure to very low concentrations of BPA by pregnant females can cause fetal abnormalities in primates

Bisphenol A (BPA) is a chemical that is used in a wide variety of consumer products, such as resins used to line metal food and beverage containers, thermal paper store receipts, and dental composites. [More]

New report reveals prevalence of heroin-related overdose deaths in Kentucky

A new report from the Kentucky Injury Prevention and Research Center (KIPRC) reveals the prevalence and charges associated with drug overdose in the Bluegrass state. [More]

Alere's Connected Health technologies to be demonstrated at HIMSS 2014 Annual Conference

Alere Inc., a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health information solutions, today announced that Alere will demonstrate its Connected Health technologies at the HIMSS 2014 Annual Conference to help providers, payers and accountable care organizations improve care coordination, identify gaps in care, and drive healthy patient behaviors. [More]